In a newly published study, an algorithm developed at NIH shows promise for improving early detection of cervical cancer in low-resource areas, where 80 percent of cases occur.
Run by the daughter of a renowned genetic oncologist, CancerIQ is expanding and raising money as it rolls out its testing management and clinical decision support technology.
The company published data from a 1,102-patient trial that found that amino acid markers could be useful for diagnosing the condition in a subset of patients.
With a University of Missouri partnership, Roche is testing the combination of data from disparate sources and furthering the integration of several recent acquisitions.
Pro-Lab will shepherd Medicortex's kit through the regulatory processes in Canada and the UK, as well as clinically validate it. It will have exclusive rights to sell the kit in the two nations.
The firm expects to build out a menu for the reader, which will automate results reporting for colorimetric- and fluorescence-based tests.
Farsight Genome Systems is touting the rapid scalability of its analytic pipeline as it seeks to make its technology "future-proof" for clinical genomics labs.
The device is an electrochemical lateral flow immunosensor test that will initially be used to detect dengue hemorrhagic fever, and later, to assess stroke severity.
Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
The immunochromatographic approach detects not only the presence of a substance in a sample, but its amount by visualizing its concentration using gold nanoparticles.